NASDAQ · CVRXHealthcareSurgical Instruments

CVRx financials

$2.63+1.54%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$56.7M$51.3M$39.3M$22.5M$13.0M
Gross profit$48.3M$43.0M$33.0M$17.5M$9.4M
Gross margin85.3%83.8%84.1%77.8%72.1%
Operating income-$51.3M-$59.5M-$43.1M-$42.5M-$26.0M
Net income-$53.3M-$60.0M-$41.2M-$41.4M-$43.1M
Net margin−94.1%−116.9%−104.8%−184.4%−330.5%
Diluted EPS$-2.04$-2.65$-1.99$-2.02$-4.16
EBITDA-$50.5M-$58.9M-$42.6M-$42.1M-$25.8M
Operating cash flow-$40.2M-$39.1M-$39.0M-$42.7M-$27.7M
Free cash flow-$40.8M-$40.5M-$39.6M-$43.4M-$28.9M
Diluted shares26.1M22.6M20.8M20.5M10.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$75.7M$105.9M$90.6M$106.2M$142.1M
Short-term investments$0.00$0.00$0.00$0.00—
Total debt$49.5M$49.3M$29.2M$6.7M$0.00
Total assets$104.8M$133.4M$115.2M$124.9M$152.5M
Total liabilities$65.5M$62.4M$39.3M$15.8M$6.6M
Shareholders' equity$39.3M$71.1M$75.9M$109.2M$146.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology